An accelerated dose escalation with a grass pollen allergoid is safe and well-tolerated: a randomized open label phase II trial

Conclusions: The dose escalation of a grass pollen allergoid can be accelerated with safety and tolerability profiles comparable to the conventional dose escalation.
Source: Epidemiologic Perspectives and Innovations - Category: Epidemiology Authors: Source Type: research